A randomized, double-blind, double-dummy comparison of the efficacy and tolerability of low-dose transdermal buprenorphine (BuTrans® seven-day patches) with buprenorphine sublingual tablets (Temgesic®) in patients with osteoarthritis pain

Journal of Pain and Symptom Management

Volumn 40, Issue 2, 2010, Pages 266-278

  James, Ian G V ^a   O'Brien, Catherine M ^b   McDonald, Chris J ^c  

^a Spring House Surgery   (United Kingdom)

^b Fincham Statistics   (United Kingdom)

^c Napp Pharmaceuticals Limited   (United Kingdom)

Author keywords

7 day; buprenorphine; low dose; osteoarthritis; pain; patches; sublingual; transdermal

Indexed keywords

BUPRENORPHINE; BUTRANS; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; ASTHENIA; CHRONIC PAIN; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG ADMINISTRATION ROUTE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HEADACHE; HIP OSTEOARTHRITIS; HUMAN; KNEE OSTEOARTHRITIS; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; NAUSEA; OSTEOARTHRITIS; OUTCOME ASSESSMENT; PAIN; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SLEEP DISORDER; SOMNOLENCE; TREATMENT DURATION; TREATMENT OUTCOME; VOMITING;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, SUBLINGUAL; ANALGESICS, OPIOID; BUPRENORPHINE; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; OSTEOARTHRITIS, HIP; OSTEOARTHRITIS, KNEE; PAIN; PAIN MEASUREMENT; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 77955570378     PISSN: 08853924     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpainsymman.2010.01.013     Document Type: Article

References (50)

1. R. Likar, H. Kayser, and R. Sittl Long-term management of chronic pain with transdermal buprenorphine: a multicenter, open-label, follow-up study in patients from three short-term clinical trials Clin Ther 28 2006 943 952
2. V. Bach, M. Kamp-Jensen, N.-H. Jensen, and J. Eriksen Buprenorphine and sustained release morphine - effect and side-effects in chronic use Pain Clin 4 1991 87 93
3. De, F. Conno, C. Ripamonti, and A. Sbanotto A clinical study on the use of codeine, oxycodone, dextropropoxyphene, buprenorphine, and pentazocine in cancer pain J Pain Symptom Manage 6 1991 423 427
4. M.A. Nasar, M.A. McLeavy, and J. Knox An open study of sub-lingual buprenorphine in the treatment of chronic pain in the elderly Curr Med Res Opin 10 1986 251 255
5. H. Adriaensen, B. Mattelaer, and H. Vanmeeden A long-term open, clinical and pharmacokinetic assessment of sublingual buprenorphine in patients suffering from chronic pain Acta Anaesthiol Belg 36 1985 33 40
6. S.L. Blamey, I.G. Finlay, D.C. Carter, and C.W. Imrie Analgesia in acute pancreatitis: comparison of buprenorphine and pethidine BMJ 288 1984 1494 1495
7. V. Ventafridda, F. De Conno, G. Guarise, M. Tamburini, and G. Savio Chronic analgesic study on buprenorphine action in cancer pain Arzneimittelforschung 33 1983 587 590
8. A.H.B. Masson Sublingual buprenorphine versus oral dihydrocodeine in post-operative pain J Int Med Res 9 1981 506 510
9. P. Huang, G.B. Kehner, and A. Cowan Comparison of pharmacological activities of buprenorphine and norbuprenorphine: norbuprenorphine is a potent opioid agonist J Pharmacol Exp Ther 297 2001 688 695
10. A. Cowan, E. Friderichs, and Staßburger Basic pharmacology of buprenorphine K. Budd, R.B. Raffa, Buprenorphine - the unique opioid analgesic 2005 Thieme New York 3 21
11. S. Ide, M. Minami, and M. Satoh Buprenorphine antinociception is abolished, but naloxone-sensitive reward is retained, in μ-opioid receptor knockout mice Neuropsychopharmacology 29 2004 1656 1663
12. J. Brainin-Mattos, N.D. Smith, and S. Malkmus Cancer-related bone pain is attenuated by a systemically available δ-opioid receptor agonist Pain 122 2006 174 181
13. A. Dahan, A. Yassen, and H. Bijl Comparison of the respiratory effects of intravenous buprenorphine and fentanyl in humans and rats Br J Anaesth 94 2005 825 834
14. A. Dahan, A. Yassen, and R. Romberg Buprenorphine induces ceiling in respiratory depression but not in analgesia Br J Anaesth 96 2006 627 632
15. S.L. Walsh, K.L. Preston, M.L. Stitzer, E.J. Cone, and G.E. Bigelow Clinical pharmacology of buprenorphine: ceiling effects at high doses Clin Pharmacol Ther 55 1994 569 580
16. R.A. Boas, and J.W. Villiger Clinical actions of fentanyl and buprenorphine. The significance of receptor binding Br J Anaesth 57 1985 192 196
17. J.W. Villiger, and K.M. Taylor Buprenorphine: characteristics of binding sites in the rat central nervous system Life Sci 29 1981 2699 2708
18. D.V. Romero, J.S. Partilla, and Q.X. Zheng Opioid peptide receptor studies. 12. Buprenorphine is a potent and selective mu/kappa antagonist in the [35S]-GTP-gamma-S functional binding assay Synapse 34 1999 83 94
19. P.M. Kearney, C. Baigent, and J. Godwin Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials BMJ 332 2006 1302 1308
20. J.L. Goldstein Challenges in managing NSAID-associated gastrointestinal tract injury Digestion 69 2004 25 33
21. C. Bombardier, L. Laine, and A. Reicin Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis N Engl J Med 343 2000 1520 1528
22. R.E. Bullingham, H.J. McQuay, D. Dwyer, M.C. Allen, and R.A. Moore Sublingual buprenorphine used postoperatively: clinical observations and preliminary pharmacokinetic analysis Br J Clin Pharmacol 12 1981 117 122
23. R. Langford, F. McKenna, S. Ratcliffe, J. Vojtassák, and U. Richarz Transdermal fentanyl for improvement of pain and functioning in osteoarthritis: a randomized, placebo-controlled trial Arthritis Rheum 54 2006 1829 1837
24. C.S. Cleeland, and K.M. Ryan Pain assessment: global use of the Brief Pain Inventory Ann Acad Med Singapore 23 1994 129 138
25. N. Bellamy, W.W. Buchanan, C.H. Goldsmith, J. Campbell, and L.W. Stitt Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee J Rheumatol 15 1988 1833 1840
26. N. Bellamy, W.W. Buchanan, C.H. Goldsmith, J. Campbell, and L.W. Stitt Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes following total knee or hip arthroplasty in osteoarthritis J Orthopaed Rheumatol 1 1988 95 108
27. R.O. Potts, and R.A. Lobo Transdermal drug delivery: clinical considerations for the obstetrician-gynecologist Obstet Gynecol 105 2005 953 961
28. J.F. Burris, V. Papademetriou, J.D. Wallin, M.E. Cook, and D.J. Weidler Therapeutic adherence in the elderly: transdermal clonidine compared to oral verapamil for hypertension Am J Med 91 1991 22S 28S
29. A. Cano Compliance to hormone replacement therapy in menopausal women controlled in a third level academic centre Maturitas 20 1994 91 99
30. L. Allan, H. Hays, and N.H. Jensen Randomised crossover trial of transdermal fentanyl and sustained release oral morphine for treating chronic non-cancer pain BMJ 322 2001 1154 1158
31. R.C. Heel, R.N. Brogden, T.M. Speight, and G.S. Avery Buprenorphine: a review of its pharmacological properties and therapeutic efficacy Drugs 17 1979 81 110
32. Reidenberg B, Eltahtawy A, Munera C, et al. Daily pharmacokinetic performance of a buprenorphine transdermal system (BTDS) for up to 7 days [abstract]. Proceedings of the 30th Annual American College of Clinical Pharmacy Meeting, October 18-21, 2009, Anaheim, California, p. 1027.
33. R.K. Simpson, E.A. Edmondson, C.F. Constant, and C. Collier Transdermal fentanyl as treatment for chronic low back pain J Pain Symptom Manage 14 1997 218 224
34. T.J. Gana, M.L.G. Pascual, and R.R.B. Fleming Extended-release tramadol in the treatment of osteoarthritis: a multicenter, randomized, double-blind, placebo-controlled clinical trial Curr Med Res Opin 22 2006 1391 1401
35. N. Babul, R. Noveck, and H. Chipman Efficacy and safety of extended-release, once-daily tramadol in chronic pain: a randomized 12-week clinical trial in osteoarthritis of the knee J Pain Symptom Manage 28 2004 59 71
36. P.M. Peloso, N. Bellamy, and W. Bensen Double blind randomized placebo control trial of controlled release codeine in the treatment of osteoarthritis of the hip or knee J Rheumatol 27 2000 764 771
37. N. Katz Methodological issues in clinical trials of opioids for chronic pain Neurology 65 2005 S32 S49
38. G. Peat, R. McCarney, and P. Croft Knee pain and osteoarthritis in older adults: a review of community burden and current use of primary care Ann Rheum Dis 60 2001 91 97
39. Medicines and Healthcare products Regulatory Agency Cardiovascular safety of non-steroidal anti-inflammatory drugs: Overview of key data 2005 MHRA London, UK
40. M.J. Langman, J. Weil, and P. Wainwright Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs Lancet 343 1994 1075 1078
41. M.S. Cepeda, F. Camargo, C. Zea, and L. Valencia Tramadol for osteoarthritis Cochrane Database Syst Rev 3 2006 CD005522
42. 63Ni electron-capture gas chromatographic assay for buprenorphine and metabolites in human urine and feces J Chromatogr 337 1985 291 300
43. A. Polettini, and M.A. Huestis Simultaneous determination of buprenorphine, norbuprenorphine, and buprenorphine-glucuronide in plasma by liquid chromatography-tandem mass spectrometry J Chromatogr B Biomed Sci Appl 754 2001 447 459
44. D.E. Moulin, M.B. Max, and R.F. Kaiko The analgesic efficacy of intrathecal D-Ala2-D-Leu5-enkephalin in cancer patients with chronic pain Pain 23 1985 213 221
45. B.M. Onofrio, and T.L. Yaksh Intrathecal delta-receptor ligand produces analgesia in man [letter] Lancet 1 1983 1386 1387
46. M.L. Jensen, D. Foster, and R. Upton Comparison of cerebral pharmacokinetics if buprenorphine and norbuprenorphine in an in vivo sheep model Xenobiotica 37 2007 441 457
47. M. Baba, R. Oishi, and K. Saeki Enhancement of blood-brain barrier permeability to sodium fluoroscein by stimulation of μ opioid receptors in mice Naunyn-Schmiedeberg's Arch Pharmacol 337 1988 423 428
48. C.J. Landau, W.D. Carr, and A.J. Razzetti Buprenorphine transdermal delivery system in adults with persistent noncancer-related pain syndromes who require opioid therapy: a multicenter, 5-week run-in and randomized, double-blind maintenance-of-analgesia study Clin Ther 31 2007 2179 2193
49. D.A. Spyker, M.E. Hale, and M. Lederman Long-term use of buprenorphine transdermal system (BTDS) in patients with chronic pain [abstract] J Am Geriatr Soc 50 Suppl 4 2002 S66
50. Conaghan P, Schofield JP, O'Brien C. A head-to-head comparison of BuTrans® (buprenorphine transdermal patches) versus co-codamol in elderly patients with severe hip and knee osteoarthritis [abstract]. Annual European Congress of Rheumatology, June 11-14, 2008, Paris, France.